Presentation from Stefan Geschwindner (AstraZeneca) at the 6th edition of NovAliX conference, including data on our collaboration on challenging membrane protein targets with Salipro® and SPR.
Salipro Biotech signs multi-target agreement with an additional global pharma company. Salipro Biotech will apply its expertise and its unique membrane protein technology to advance programs on challenging targets selected by the pharmaceutical partner.
Salipro Biotech receives notice of allowance from U.S. Patent and Trademark Office relevant to its Salipro® technology for the stabilisation of drug targets
We're growing and moving to new premises in central Stockholm. With more lab space and offices, we're located at the Greenhouse Labs at the Royal Institute of Technology in Stockholm. Location
Stefan Geschwindner, Principal Scientist, AstraZeneca R&D Gothenburg:
“We have been impressed by the fact that Salipro Biotech is able to work both with detergent-solubilised material as well as with crude cell-membranes and furthermore demonstrated good feasibility to generate non-aggregated membrane proteins in a detergent-free form. This forms an excellent basis for the next steps that will include both structural and biophysical work.”
The Salipro® technology is covered in the news (selected articles):
Breakthrough Nanoparticle Technology to Study Structure of Membrane Proteins in Lipid Environment
Nanoparticles Reveal Membrane Proteins' Structure and Function
Novel nanoparticle technology can decipher protein structures and help access drug targets